PharmaTelevision - The GI Company: Specialists in GI Medicine

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The GI Company: Specialists in GI Medicine

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview, Fintan Walton talks to Nicholas Barker, President and CEO of The GI Company. The interview commences with Nicholas discussing the academic origins of The GI Company, its technologies and its financial sources. Nicholas talks about the company’s lead programme, known as Intestinal Trefoil Factor (ITF) and explains how ITF promotes mucosal repair, thus giving the drug scope to treat several conditions. Nicholas mentions the benefits of applying a virtual company structure to The GI Company, and also covers the key attributes of a company wishing to partner the ITF programme. The interview is concluded with the prospects for ITF and its development for treating a range of indications.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The GI Company: origins , technologies and financial sources.

Fintan Walton:

Hello and welcome to PharmaVentures business review here in Madrid. On this show I've got Nicholas Barker, who is President and CEO of The GI Company. Welcome to the show.

Nicholas Barker:

Thank you Fintan Walton, delighted to be here.

Fintan Walton:

Nicholas Barker, The GI Company is a company obviously very specialized in the GI Area, your were originally founded in 2000 and you're a private based, privately based company, tell us about why GI was the area of focus, and how the company was set up?

Nicholas Barker:

We set up two scientific co-founders as a company, Professor Dan Podolsky, Massachusetts General Hospital, and Professor Chung Owyang in the University of Michigan and they are well renown Gastroenterologists and so it's logical to that be the emphasis of the company.

Fintan Walton:

And when the company was founded there was already products or technology that was available?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Nicholas Barker

President and Chief Executive Officer

Dr Nicholas Barker, President and CEO of The GI Company, is a licensed UK pharmacist and holds a PhD in drug targeting and delivery. He has over 20 years of pharmaceutical product development experience, and has held senior executive roles in international business and management at a number of large pharmaceutical and smaller biotechnology companies. Dr Nicholas Barker has significant experience in preclinical and clinical drug development, manufacture and industrialization, as well as product registration and launch. During his industry career he has contributed to a number of successful product introductions including Nasacort Aq, Synercid, Taxotere, Plenaxis ,Menorest and Dilacor XR.

The GI Company

The GI Company is a privately held, specialty biopharmaceutical company established to meet the clinical needs and commercial opportunities available in the field of gastrointestinal medicine. The GI Company strategy for success is to discover and develop products in key gastrointestinal indications with high medical need, identify and exploit 'development-ready' technologies for the near-term to reduce risks for shareholders and build a novel pipeline of products based on cutting-edge science in the gastrointestinal field, through leveraging resources from academic institutions and corporate partners.